AMP Capital Investors Ltd boosted its position in shares of Teleflex Incorporated (NYSE:TFX) by 29.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 37,691 shares of the medical technology company’s stock after purchasing an additional 8,520 shares during the period. AMP Capital Investors Ltd owned 0.08% of Teleflex worth $9,379,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TFX. Rock Springs Capital Management LP bought a new position in shares of Teleflex in the fourth quarter worth about $22,829,000. Aristotle Atlantic Partners LLC bought a new position in shares of Teleflex in the fourth quarter worth about $202,000. BlueCrest Capital Management Ltd increased its stake in shares of Teleflex by 113.9% in the fourth quarter. BlueCrest Capital Management Ltd now owns 2,454 shares of the medical technology company’s stock worth $611,000 after purchasing an additional 1,307 shares during the period. Thrivent Financial For Lutherans increased its stake in shares of Teleflex by 1.2% in the fourth quarter. Thrivent Financial For Lutherans now owns 188,185 shares of the medical technology company’s stock worth $46,824,000 after purchasing an additional 2,284 shares during the period. Finally, Miura Global Management LLC bought a new position in shares of Teleflex in the fourth quarter worth about $12,441,000. 90.75% of the stock is owned by hedge funds and other institutional investors.
NYSE TFX traded down $5.38 during trading on Friday, reaching $246.68. 215,139 shares of the company traded hands, compared to its average volume of 328,998. The company has a current ratio of 2.33, a quick ratio of 1.51 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $11,355.12, a price-to-earnings ratio of 29.37, a PEG ratio of 1.86 and a beta of 1.18. Teleflex Incorporated has a 1-year low of $191.40 and a 1-year high of $288.78.
Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, February 22nd. The medical technology company reported $2.44 earnings per share for the quarter, beating analysts’ consensus estimates of $2.40 by $0.04. The company had revenue of $595.10 million for the quarter, compared to the consensus estimate of $601.17 million. Teleflex had a return on equity of 16.46% and a net margin of 7.11%. The company’s quarterly revenue was up 15.8% on a year-over-year basis. During the same period in the previous year, the business earned $2.13 earnings per share. analysts predict that Teleflex Incorporated will post 9.66 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, March 15th. Stockholders of record on Friday, March 2nd were issued a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 0.55%. The ex-dividend date was Thursday, March 1st. Teleflex’s payout ratio is currently 16.19%.
In other news, Director Benson Smith sold 9,331 shares of the business’s stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $251.49, for a total value of $2,346,653.19. Following the transaction, the director now directly owns 83,711 shares of the company’s stock, valued at approximately $21,052,479.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director George Babich, Jr. sold 2,500 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $263.38, for a total value of $658,450.00. Following the completion of the transaction, the director now directly owns 10,583 shares in the company, valued at $2,787,350.54. The disclosure for this sale can be found here. Insiders sold a total of 25,890 shares of company stock worth $6,693,722 over the last three months. 2.39% of the stock is owned by company insiders.
A number of research firms have recently commented on TFX. Leerink Swann reiterated a “buy” rating and issued a $321.00 price objective (up from $307.00) on shares of Teleflex in a research note on Tuesday, January 30th. ValuEngine lowered Teleflex from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Stephens reissued a “buy” rating and set a $300.00 target price on shares of Teleflex in a research report on Thursday, January 18th. TheStreet downgraded Teleflex from an “a-” rating to a “c+” rating in a research report on Monday, March 12th. Finally, Goldman Sachs began coverage on Teleflex in a research report on Wednesday. They set a “neutral” rating and a $257.00 target price on the stock. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $279.10.
WARNING: “Teleflex Incorporated (NYSE:TFX) Shares Bought by AMP Capital Investors Ltd” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/07/teleflex-incorporated-tfx-stake-increased-by-amp-capital-investors-ltd.html.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.